Real-World Experiences with ONAPGO™ for Parkinson's Disease
This study is looking at the real-world experiences of people with Parkinson's disease who are using Continuous Subcutaneous Apomorphine Infusion (ONAPGO™). Researchers want to understand how long it takes to find the right dose of ONAPGO™, how often other Parkinson's medications are adjusted, and how many visits or dose changes are needed to reach the best dose. You can join if you are 18 or older, have a prescription for ONAPGO™ as part of your regular care, and have chosen to receive support from a Clinical Nurse Navigator (a nurse specially trained in Parkinson's disease). The study aims to include 120 participants, but its current status is unclear.
- Study design
- This is an observational study, meaning researchers will watch and collect information about your experience with ONAPGO™ as part of your standard care. It is a Phase 4 study, which typically means it's conducted after a drug has been approved for use.
- What's involved
- You will be observed from the time you get your ONAPGO™ prescription, through in-home education, dose initiation, titration, optimization, and maintenance periods. The study will also include standard care visits with your Clinical Nurse Navigator and an end-of-study visit.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcomes, such as titration duration and medication adjustments, will be measured at approximately 52-60 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:
At a glance
Conditions
NCT07219927
Where you'd take part
This study runs at 5 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Parkinson's Disease & Movement Disorders Center of Boca Raton
Boca Raton, Floridano site contact published
Recruiting
Parkinson's Disease and Movement Disorders Center - Long Island
Commack, New Yorkno site contact published
Recruiting
Parkinson's Disease and Movement Disorders Center - Orange County (North)
Irvine, Californiano site contact published
Recruiting
Parkinson's Disease and Movement Disorders Center - Orange County (South)
Aliso Viejo, Californiano site contact published
Recruiting
Parkinson's Research Centers of America - Palo Alto
Palo Alto, Californiano site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Mindy Grall, PhD ANP-BC · STUDY_CHAIR · Supernus Pharmaceuticals, Inc.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Titration Duration and Time to Optimized DoseApproximately 52-60 weeks
The time from the date of ONAPGO™ initiation to the date of Dose Optimization Confirmation, as documented by the HCP/Investigator Unit of Measure: days
- Concomitant Parkinson's Disease (PD) Medication AdjustmentsApproximately 52-60 week
Percentage of participants requiring ≥1 adjustment to their concomitant PD medications, as documented by the HCP/Investigator. "Percentage of participants"
- The number of titration visits or dose adjustments required to reach the final optimized dose. This is a count of a specific eventApproximately 52-60 weeks
Number of titration visits or infusion adjustments to reach final optimized dose; Unit of Measure: count per participant